vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $13.3M, roughly 1.6× Laird Superfood, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -373.3%, a 360.1% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
AUTL vs LSF — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $13.3M |
| Net Profit | $-79.1M | $-1.8M |
| Gross Margin | — | 34.1% |
| Operating Margin | -337.9% | -13.5% |
| Net Margin | -373.3% | -13.2% |
| Revenue YoY | — | 15.0% |
| Net Profit YoY | 3.6% | -341.4% |
| EPS (diluted) | $-0.30 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.3M | ||
| Q3 25 | $21.2M | $12.9M | ||
| Q2 25 | $20.9M | $12.0M | ||
| Q1 25 | $9.0M | $11.7M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | $0 | $11.8M | ||
| Q2 24 | $0 | $10.0M | ||
| Q1 24 | $10.1M | $9.9M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-79.1M | $-975.1K | ||
| Q2 25 | $-47.9M | $-362.2K | ||
| Q1 25 | $-70.2M | $-156.2K | ||
| Q4 24 | — | $-398.4K | ||
| Q3 24 | $-82.1M | $-166.1K | ||
| Q2 24 | $-58.3M | $-239.1K | ||
| Q1 24 | $-52.7M | $-1.0M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | — | -13.5% | ||
| Q3 25 | -337.9% | -7.7% | ||
| Q2 25 | -292.6% | -3.3% | ||
| Q1 25 | -726.3% | -1.9% | ||
| Q4 24 | — | -4.1% | ||
| Q3 24 | — | -2.3% | ||
| Q2 24 | — | -3.4% | ||
| Q1 24 | -384.1% | -11.0% |
| Q4 25 | — | -13.2% | ||
| Q3 25 | -373.3% | -7.6% | ||
| Q2 25 | -229.0% | -3.0% | ||
| Q1 25 | -781.1% | -1.3% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | — | -1.4% | ||
| Q2 24 | — | -2.4% | ||
| Q1 24 | -522.1% | -10.3% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.18 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.22 | — | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $11.5M |
| Total Assets | $661.9M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | $86.1M | $5.1M | ||
| Q2 25 | $123.8M | $3.9M | ||
| Q1 25 | $95.8M | $7.0M | ||
| Q4 24 | — | $8.3M | ||
| Q3 24 | $657.1M | $7.9M | ||
| Q2 24 | $705.9M | $7.6M | ||
| Q1 24 | $758.5M | $7.1M |
| Q4 25 | — | $11.5M | ||
| Q3 25 | $265.5M | $12.8M | ||
| Q2 25 | $346.5M | $13.4M | ||
| Q1 25 | $371.1M | $13.3M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $477.0M | $13.1M | ||
| Q2 24 | $527.8M | $12.6M | ||
| Q1 24 | $582.0M | $12.7M |
| Q4 25 | — | $19.2M | ||
| Q3 25 | $661.9M | $18.9M | ||
| Q2 25 | $721.0M | $20.4M | ||
| Q1 25 | $746.3M | $21.5M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | $827.5M | $18.8M | ||
| Q2 24 | $853.6M | $18.0M | ||
| Q1 24 | $901.4M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $68.4K |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $68.4K | ||
| Q3 25 | $-67.9M | $1.2M | ||
| Q2 25 | $-72.8M | $-2.8M | ||
| Q1 25 | $-75.6M | $-1.3M | ||
| Q4 24 | — | $339.2K | ||
| Q3 24 | $-76.7M | $305.8K | ||
| Q2 24 | $-51.1M | $642.7K | ||
| Q1 24 | $-40.5M | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $-41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -406.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUTL
Segment breakdown not available.
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
